Eiger BioPharmaceuticals (EIGR) Doses First Patient in Phase 2 LIMT HDV Study
- Banks, telecoms lead Wall Street up; another Dow record
- Western Digital (WDC) Raises Q2 Outlook
- bluebird bio (BLUE) to Offer $200M of Common Stock
- Dave & Buster's Entertainment (PLAY) Tops Q3 EPS by 11c, Raises FY Revenue Guidance
- After-Hours Stock Movers 12/06: (PLAY) (ANTH) (WDC) Higher; (AVAV) (ESV) (BLUE) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced that the first patient was dosed in the Phase 2 LIMT HDV (Lambda Interferon MonoTherapy in HDV) study, a monotherapy trial of pegylated interferon lambda 1a ("Lambda") as a potential treatment for chronic hepatitis D virus (HDV) infection. LIMT HDV is a 30-patient study designed to evaluate the safety, tolerability and efficacy of two dose levels of Lambda after 48 weeks of treatment. LIMT HDV is an international study currently enrolling at University of Auckland in New Zealand with additional sites planned in Israel and Pakistan.
"We are excited to begin dosing HDV-infected patients with Lambda in the LIMT HDV study," said Eduardo Martins, MD, DPhil, Senior Vice President of Liver and Infectious Diseases Drug Development at Eiger. "We plan to explore Lambda alone and in combination with lonafarnib, our lead compound in Phase 2 development to treat HDV. Eiger now has multiple active anti-HDV agents in development, including an oral therapy and a subcutaneous injectable therapy to study alone and in combination toward the suppression or cure of HDV."
"Over recent years, patients with chronic hepatitis B and hepatitis C have benefited from huge advances in antiviral therapy for both diseases. Unfortunately HDV remains a huge unmet medical need because of the lack of any effective therapy for this most aggressive form of viral hepatitis. In many countries, HDV presents a real public health challenge," said Edward Gane, MD, Principal Investigator and Professor of Medicine at University of Auckland, New Zealand, and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit, Auckland City Hospital. "We are delighted to have enrolled the first patient in LIMT HDV, a study that may lay the groundwork for development of Lambda in HDV infection."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Therapeutics (VKTX) Announces FDA Orphan Drug Designation for VK0214 to Treat X-ALD
- MasterCard (MA) Raises Quarterly Dividend 15.8% to $0.22; Announces New $4B Stock Buyback Plan
- Tyson Foods (TSN) Expands Boar to 11 and Elects Jeffrey Schomburger
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!